Holding(s) in Company

RNS Number : 2343M

Hikma Pharmaceuticals Plc

26 January 2009

 

Notification of major interests in shares

LONDON, 26 January 2009 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

2	Reason for the notification	Yes/no
	An acquisition or disposal of voting rights	Yes
	An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached
	An event changing the breakdown of voting rights
	Other (please specify): Compliance with the Transparency Directive

3	Full name of the person subject to the notification obligation	Legal & General Group Plc (L&G)
4	Full name of shareholders if different from above	-
5	Date of the Transaction (and date on which the threshold crossed is reached differently)	22 January 2009
6	Date on which the issuer notified	23 January 2009
7	Threshold that is crossed	Below 3% (L&G)
8	Notified details:

A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
	Number of shares	Number of voting rights	Number of shares		Number of voting rights		% of voting rights
			Direct	Indirect	Direct	Indirect	Direct	Indirect
Ordinary Shares (0.10 GBP)	5,181,598	5,181,598	Below 3%

B. Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights that may be acquired if the instrument if exercised/converted	% of voting rights

Total A+B
Number of Voting rights	% of voting rights
Below 3%

9

Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable

Legal & General Group Plc (Direct and Indirect) (Group)   Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)   Legal & General Investment Management Limited (Indirect) (LGIM)  Legal & General Group Plc (Direct) (L&G) (Below 3% = LGAS, LGPL & PMC) Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)  Legal & General Insurance Holdings Limited (Direct) (LGIH)  Legal & General Assurance (Pensions Management) Limited (PMC)   Legal & General Assurance Society Limited (LGAS & LGPL)  Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting
10	Name of the proxy holder	N/A
11	Number of voting rights proxy holder will cease to hold	N/A
12	Date on which proxy holder will cease to hold voting rights	N/A

13

Additional Information

Notification using the total voting rights figure of  189,237,607

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Henry Knowles Company Secretary	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: 'Branded', 'Injectables' and 'Generics', based principally in the Middle East and North Africa ('MENA'), where it is a market leader and sells across 17 countries, the United States and Europe. In 2007, Hikma achieved revenues of $449 million and profit attributable to shareholders of $63 million. At 31 December 2007, the Group had over 3,000 employees. For news and other information, please visit www.hikma.com.

 

END

 

 

HOLUNAARKARAUAR